| Symbol | AB |
|---|---|
| Name | ALLIANCEBERNSTEIN HOLDING L.P. |
| Sector | FINANCE |
| Region | North America |
| Industry | Investment Managers |
| Address | 501 COMMERCE STREET, NASHVILLE, Tennessee, 37203, United States |
| Telephone | +1 615 622-0000 |
| Fax | — |
| — | |
| Website | https://www.alliancebernstein.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000825313 |
| Description | AllianceBernstein provides investment management services to institutional (45% of assets under management), retail (39%), and private (16%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2022, AB had $647.0 billion in managed assets, composed primarily of fixed-income (41% of AUM) and equity (43%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder. The company also provides sell-side research and brokerage services through its Sanford Bernstein subsidiary. Additional info from NASDAQ: |
AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
Read moreAB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026
Read moreAB Science annonce aujourd’hui le succès d’augmentations de capital d’un montant brut total de 14,2 millions d’euros
Read moreAB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
Read moreCAIS Welcomes New Strategic Investors, Valuing the Company at Over $2 Billion
Read more(99% Neutral) ALLIANCEBERNSTEIN HOLDING L.P. (AB) Reports Q3 2026 Financial Results
Read moreAB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
Read moreAB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
Read more